Back to Search Start Over

Novel indications for <TOGGLE>BRCA</TOGGLE>1 screening using individual clinical and morphological features

Authors :
Eisinger, François
Noguès, Catherine
Guinebretière, Jean-Marc
Peyrat, Jean-Philippe
Bardou, Valérie-Jeanne
Noguchi, Tetsuro
Vennin, Philippe
Sauvan, Richard
Lidereau, Rosette
Birnbaum, Daniel
Jacquemier, Jocelyne
Sobol, Hagay
Source :
International Journal of Cancer; 21 June 1999, Vol. 84 Issue: 3 p263-267, 5p
Publication Year :
1999

Abstract

Since there is a lack of common family profile among BRCA1-gene carriers, and since the risk of being a mutation carrier is not limited to women with a family history of breast or ovarian cancer, multivariate statistical analysis using the logistic-regression model was carried out, to discriminate between sporadic cases and BRCA1-breast cancers (BRCA1-BCs), especially when information about the family history of breast/ovarian cancer and ethnicity are irrelevant or unavailable, in order to offer specific medical treatment to this population. We examined 32 BRCA1-BCs selected at cancer genetic clinics and 200 consecutive controls without family history of breast cancer for age at onset and current morphological parameters. Following the multivariate analysis, 3 parameters only, namely, early age at cancer onset [odds ratio (OR) for each year = 1.16; p &amp;lt; 0.0001], estrogen-receptor negativity (OR = 5.7; p = 0.01) and poor differentiation (OR = 5; p = 0.03) were found significant factors for predicting BRCA1-carrier status. The expected impact in BRCA1 screening of our model was estimated using data on 5 700 breast-cancer cases from a hospital-based registry. Only 50 and 15% of tumours with early age at onset below 35 years present one or the other 2 discriminant parameters respectively. Consequently, whereas the probability of finding a BRCA1 mutation is rated low (6.2%) when the sole criterion of early onset up to the age of 35 years is used, based on our model, in the sub-group of women with a tumor that is both estrogen-receptor-negative and poorly differentiated the mutation-detection rate is predicted to be above the 10% chance level recommended by the ASCO guidelines. This sub-group of women, representing about 1% of all breast-cancer cases in Western countries, consequently deserves to be tested. Int. J. Cancer (Pred. Oncol.) 84:263–267, 1999. &#169; 1999 Wiley-Liss, Inc.

Details

Language :
English
ISSN :
00207136 and 10970215
Volume :
84
Issue :
3
Database :
Supplemental Index
Journal :
International Journal of Cancer
Publication Type :
Periodical
Accession number :
ejs1284310
Full Text :
https://doi.org/10.1002/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO;2-G